Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lexicon Pharmaceuticals has said that data from a Phase I clinical trial for its irritable bowel syndrome drug was found to be generally well-tolerated at all dose levels and exposure levels in blood were low.
Subscribe to our email newsletter
A statistically significant reduction of urinary 5-hydroxyindoleacetic acid, a metabolite of serotonin and biomarker for serotonin production, was observed in subjects who received the highest dose tested, 2,000mg per day, for 2 weeks. Over the 14 day trial, no dose-limiting toxicities were observed.
Philip Brown, Lexicon’s vice president of clinical development, said: “We are pleased with the results of our initial human studies of LX1031. The compound was well tolerated, consistent with our preclinical observations, and we are encouraged by the 5-hydroxyindoleacetic acid (5-HIAA) biomarker results. We look forward to progressing LX1031 into phase II clinical trials in 2008.”